购物车
您的购物车当前为空
KNa1.1-IN-2 (Compound Z05) 是一种具备血脑屏障穿透能力的选择性KNa1.1通道抑制剂,对hERG通道发挥显著作用。它通过结合KNa1.1通道并阻断由于Gain-of-function (GOF) 突变导致的通道活性,来有效干预与KCNT1相关的癫痫发作。该化合物对GOF突变体Y796H也表现出抑制效果,因此,KNa1.1-IN-2 有望用于研究与KCNT1相关的癫痫疾病。

KNa1.1-IN-2 (Compound Z05) 是一种具备血脑屏障穿透能力的选择性KNa1.1通道抑制剂,对hERG通道发挥显著作用。它通过结合KNa1.1通道并阻断由于Gain-of-function (GOF) 突变导致的通道活性,来有效干预与KCNT1相关的癫痫发作。该化合物对GOF突变体Y796H也表现出抑制效果,因此,KNa1.1-IN-2 有望用于研究与KCNT1相关的癫痫疾病。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | 待询 | 10-14周 | |
| 50 mg | 待询 | 10-14周 |
| 产品描述 | KNa1.1-IN-2 (Compound Z05) is a selective KNa1.1 channel inhibitor capable of penetrating the blood-brain barrier, and exhibits significant efficacy on hERG channels. It binds to KNa1.1 channels, effectively blocking channel activity caused by Gain-of-function (GOF) mutations, thus intervening in KCNT1-related seizures. Additionally, it inhibits the GOF mutant Y796H, making KNa1.1-IN-2 a promising candidate for research into KCNT1-associated epilepsy disorders. |
| 分子量 | 345.48 |
| 分子式 | C24H27NO |
| CAS No. | 3037315-44-6 |
| Smiles | O(C=1C=CC=2C=CC=CC2C1CCC3CCNCC3)CC=4C=CC=CC4 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多